	GlaxoSmithKline (GSK) announced plans to expand production capacity of key components of the adjuvant system used in several of the company’s vaccines, with an investment of $100 million in its manufacturing site in Hamilton, MT.

	“For more than a decade, our Hamilton facility has supported GSK’s adjuvant system development program,” said Jack Bailey, president, US Pharmaceuticals, GSK in an April 24, 2019 press statement announcing the investment. “By expanding the adjuvant system production capabilities in Hamilton, we will continue to deliver long-term and sustainable supply for key vaccines, including SHINGRIX.”

	The company reports that the site expansion is expected to add temporary construction and contracting jobs, as well as new permanent positions, including scientists, engineers, and manufacturing and quality professionals.

	Hamilton is one of nine GSK manufacturing sites in the United States, and 86 sites globally.

Bio/Pharma Business

Bio/Pharma News

Biologic Drugs

Dosage Forms

Manufacturing, Vaccines

PharmTech News

Expansion at GSK’s Hamilton, MT site is designed to boost vaccine production capacity.